MAIA Biotechnology, Inc.
MAIA$55M
Micro CapNASDAQPharmaceutical Preparations🇺🇸North AmericaCHICAGO13 employees
MAIA Biotechnology, Inc. is a public, immune-oncology company based in Chicago, IL focused on the development of telomere targeting agents for the treatment of telomerase-positive cancer cells.
Drugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
1
Next Catalyst
Jun 30, 2026
15wMarket Overview
Stock performance and key metrics
MAIA News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
Cemiplimab
Carcinoma, Non-Small -Cell Lung
6-Thio-2'-Deoxyguanosine
Carcinoma, Non-Small-Cell Lung
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Cemiplimab | Phase 3 | Carcinoma, Non-Small -Cell Lung | - | - |
6-Thio-2'-Deoxyguanosine | Phase 3 | Carcinoma, Non-Small-Cell Lung | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply